RNLX · Renalytix PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $2.29M | $3.40M | $0 | $1.49M | - |
| Cost of Revenue | $2.13M | $2.68M | $0 | $858.0K | - |
| Gross Profit | $156.0K | $720.0K | $0 | $633.0K | - |
| R&D | $9.29M | $14.30M | $14.65M | $10.04M | $4.57M |
| SG&A | $19.75M | $28.66M | $39.52M | $23.48M | $5.75M |
| Total Operating Expenses | $29.76M | $42.94M | $54.06M | ($10.31M) | - |
| D&A | $364.0K | $508.0K | $489.0K | $282.0K | $70.0K |
| Operating Income | ($29.61M) | ($42.22M) | ($53.18M) | ($31.92M) | ($10.31M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | $4.0K | $2.0K | $0 | - | - |
| Net Income | ($33.46M) | ($45.61M) | ($45.28M) | ($35.34M) | ($9.84M) |
| EPS - Basic | ($0.31) | ($0.55) | ($0.17) | - | - |
| EPS - Diluted | ($0.31) | ($0.55) | ($0.17) | - | - |
Balance Sheet
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.68M | $24.68M | $23.82M | $39.93M | $13.29M |
| Accounts Receivable | $722.0K | $776.0K | $820.0K | $823.0K | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | - | $1.75M | $2.21M | $1.38M | $317.0K |
| Current Assets | $6.12M | $26.88M | $26.60M | $44.41M | $115.0K |
| Total Assets | $7.97M | $30.63M | $30.66M | $54.36M | $20.83M |
| Current Liabilities | $11.49M | $16.14M | $14.29M | $8.54M | $3.29M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $15.83M | $23.66M | $21.77M | $8.56M | $4.97M |
| Stockholders' Equity | ($7.85M) | $6.97M | $8.88M | $80.03M | $87.12M |
| Retained Earnings | ($211.78M) | ($178.32M) | ($155.12M) | ($112.87M) | ($52.72M) |
Cash Flow
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($30.11M) | ($34.09M) | ($45.92M) | ($28.40M) | ($9.52M) |
| Investing Cash Flow | ($4.0K) | $0 | ($662.0K) | ($751.0K) | ($1.17M) |
| Financing Cash Flow | $10.25M | $16.39M | $25.63M | $77.24M | $15.94M |
| CapEx | - | $0 | $557.0K | $773.0K | $804.0K |
| Free Cash Flow | - | ($34.09M) | ($46.48M) | ($29.17M) | ($10.33M) |
Ratios
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 6.8% | 21.2% | - | 42.5% | - |
| Operating margin | -1293.5% | -1240.7% | - | -2140.6% | - |
| EBITDA margin | -1277.6% | -1225.8% | - | -2121.7% | - |
| Net margin | -1461.6% | -1340.2% | - | -2370.0% | - |
| Free cash flow margin | - | -1001.6% | - | -1956.5% | - |
| FCF / Net income | - | 0.75 | 1.03 | 0.83 | 1.05 |
| R&D / Revenue | 405.9% | 420.2% | - | 673.4% | - |
| SG&A / Revenue | 862.9% | 842.3% | - | 1574.7% | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -419.7% | -148.9% | -147.7% | -65.0% | -47.3% |
| Return on equity | 426.0% | -654.6% | -509.6% | -44.2% | -11.3% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 0.53 | 1.67 | 1.86 | 5.20 | 0.03 |
| Quick ratio | 0.53 | 1.67 | 1.86 | 5.20 | 0.03 |
| Cash ratio | 0.41 | 1.53 | 1.67 | 4.67 | 4.04 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | -1.02 | 4.40 | 3.45 | 0.68 | 0.24 |
| Liabilities / Assets | 1.99 | 0.77 | 0.71 | 0.16 | 0.24 |
| Efficiency | |||||
| Asset turnover | 0.29 | 0.11 | 0.00 | 0.03 | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | 115d | 83d | - | 201d | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | 238d | - | 587d | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | -32.7% | - | -100.0% | - | - |
| Revenue CAGR (3y) | 15.4% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | -78.3% | - | - | - | - |
| Operating income growth (YoY) | 29.9% | 20.6% | -66.6% | -209.4% | - |
| Net income growth (YoY) | 26.6% | -0.7% | -28.1% | -259.0% | - |
| EPS growth (YoY) | 43.6% | -223.5% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | 26.7% | -59.3% | -182.5% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | - | -21.6% | -88.9% | -8.1% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-06-30.
Product / service
$4.24M totalTesting Services Revenue$2.10M · 49.5%
Licensed Products$2.00M · 47.2%
Pharmaceutical Services Revenue$140.0K · 3.3%
Stability scores
Altman Z′
FY 2024 · bankruptcy risk
-34.45
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2024 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing Renalytix plc against the 5 most active filers in the same SIC group.